Safety of elexacaftor/tezacaftor/ivacaftor dose reduction: mechanistic exploration through physiologically ‐based pharmacokinetic modeling and a clinical case series

ConclusionAlbeit in a small number of patients, this study provides evidence that reduced ETI doses in pwCF who have experienced AEs may be effective. The PBPK models enable exploration of a mechanistic basis for this finding by simulating target tissue concentrations of ETI that can be compared with drug efficacyin vitro.

Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - March 3, 2023 Category: Drugs & Pharmacology Authors: Eunjin Hong, Regina Li, Alan Shi, Lisa M. Almond, Joshua Wang, Amin Z. Khudari, Soumar Haddad, Sarkis Sislyan, Marissa Angelich, Peter S. Chung, Adupa P. Rao, Paul M. Beringer Tags: RESEARCH ARTICLE Source Type: research